AI assistant
Avidity Biosciences, Inc. — Director's Dealing 2025
Dec 19, 2025
30894_dirs_2025-12-19_8cf7e8a5-147d-4db7-9d1f-1f3305f5c499.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2025-12-17
Reporting Person: Gallagher Kathleen P. (Chief Program Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-12-17 | Common Stock | A | 72000 | — | Acquired | 122204 | Direct |
| 2025-12-17 | Common Stock | F | 33336 | $71.87 | Disposed | 88868 | Direct |
| 2025-12-17 | Common Stock | F | 8030 | $71.87 | Disposed | 80838 | Direct |
Footnotes
F1: Represents shares acquired upon the vesting of performance-based restricted stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer's common stock. The PSUs were originally granted to the Reporting Person on October 30, 2024. The PSUs were accelerated and settled on December 17, 2025 for tax planning purposes and such shares remain subject to recoupment by the Issuer if the Reporting Person's employment is terminated by the Issuer for cause or by the Reporting Person without good reason.
F2: Represents the number of shares withheld by the Issuer to cover tax withholding in connection with the settlement of PSUs on December 17, 2025.
F3: Represents the number of shares withheld by the Issuer to cover tax withholding in connection with the settlement of restricted stock units on December 17, 2025.